David L. Grange is the CEO of Pharm-Olam International, LLC, which provides a full range of clinical support to pharma and bio-tech companies. Pharm-Olam is headquartered in Houston, Texas and operates globally with regional offices in Research Triangle Park, North Carolina and Bracknell, United Kingdom.

Mr. Grange departed PPDI (Pharmaceutical Product Development, Inc.), a clinical research organization, in 2011 as CEO and as a member of the Board of Directors since 2003. As CEO he was responsible for the oversight of company clinical and laboratory operations and personnel in over 100 countries with 10,500 employees providing clinical and laboratory services to the majority of the top global pharmaceutical and biotech companies, as well as government health and research organizations.

Prior to joining PPDI, Mr. Grange served in the McCormick Foundation for 9.5 years, as President and Chief Executive Officer and earlier as Executive Vice President and Chief Operating Officer. The Foundation, one of the largest philanthropic organizations in the United States, works to advance the ideals of a free, democratic society by investing in children, communities, and country, and has granted more than $1.5 billion to organizations across the nation.

Mr. Grange served 30 years in the U.S. Army, leading from platoon through division level, with a decorated military career. His final assignments before retiring were commanding peace support operations in the Balkans.

Following 9-11, Mr. Grange was a national security consultant for CNN, CBS, and WGN. He regularly speaks and writes for a variety of companies and government institutions on leadership, organizational effectiveness, disaster preparedness, citizenship, Veterans issues, and foreign relations at home and abroad.

Mr. Grange holds a bachelor’s degree from North Georgia College and a master’s in public service from Western Kentucky University. In addition, he is the recipient of an honorary Doctor of Human Letters degrees from both Johnson & Wales University and from Aurora University.

Mr. Grange serves on the boards of the Gettysburg Foundation, Keranetics, the Boy Scouts Council, Therimunex, and Pharm-Olam International.

John Barry joined Pharm-Olam International in 2017 and serves as the Chief Operating Officer. As the Chief Operating Officer, Mr. Barry is responsible for the executive oversight of the daily operations of Pharm-Olam’s Clinical Operations, Data Management, Statistics, and Medical Writing services.

Mr. Barry has extensive experience in the drug development industry and has worked as an executive leader in a variety of functions including Alliance Management, Business Development, Clinical Operations, Contracts, Proposals and Legal. Prior to joining Pharm-Olam, Mr. Barry was the Head of Portfolio Sourcing and Relationship Management and a member of the Senior Leadership team for Merck Research Laboratories’ Global Clinical Trials Organization.

He has managed a variety of delivery models including functional, full service CRO, single service and sole source relationships. He is well versed across a variety of contract structures including value based contracting and has significant experience negotiating innovative commercial and capital models.

Prior to joining Merck, Mr. Barry spent over twenty years working for two of the top 5 global CROs. Mr. Barry has a B.S. degree from Cornell University and an MBA from the University of North Carolina at Chapel Hill.

Natalie Gassen, Pharm-Olam’s Chief Financial Officer, joined Pharm-Olam in 2015 and brings over 20 years of financial leadership experience in both private and public companies. Prior to coming to Pharm-Olam, Ms. Gassen was the Chief Financial Officer for ApoCell, Inc., a molecular biomarker company, and has previously worked in roles with progressing responsibility in several industries including banking, manufacturing, technology, and service businesses.

Dr. Yamin "Mo" Khan joined Pharm-Olam International in May 2000 and has worked in the company across various departments including Clinical Operations, Project Management, Business Development and Executive Management. Dr. Khan currently holds the post of Executive Vice President of Global Clinical Development and is responsible for Business Development, Strategic Partnerships and Executive Oversight.

Prior to joining Pharm-Olam, Dr. Khan worked at Innovex and Quintiles in Clinical and Project Management roles as well as The Liposome Company. He has a BSc in Biochemistry from the University of Liverpool and a PhD in Biochemistry from the University of Southampton.

Jason Ezzelle is the Chief Commercial and Government Contracts Officer for Pharm-Olam International. In this role, Mr. Ezzelle is responsible for the oversight of the Proposals and Contracts groups and also oversees Business Development in the area of  US Government-federally funded studies.

His over 20 year career in clinical research has provided Mr. Ezzelle with vast experiences from execution level positions to executive leadership roles in Clinical Operations, Laboratory Operations, Business Development, and Contracts and Proposal Development.

Prior to Pharm-Olam, Mr. Ezzelle started his career in research in a clinical microbiology laboratory; then joining PPD with roles of increasing responsibility in clinical operations from Clinical Research Associate, Project Manager, and Senior Project Manager. He moved into Business Development while at PPD before going to ICON Clinical Research as an Executive Director of Sales Strategy.

Jason holds a B.S. of Clinical Laboratory Science and Medical Technology from East Carolina University.

Dr. Pavle Vukojevic joined Pharm-Olam in 1997 and supports clinical operations with protocol development, therapeutic training, patient safety issues, study management and feasibility support. A native of Serbia, he received his MD in 1988 from the University of Belgrade and has also received both a Masters degree in Immunology and a specialization in Internal Medicine. Dr. Vukojevic is also a former President of the Association of Clinical Research Professional's (ACRP) Serbia Chapter, was an Assistant Professor at the Medical School University of Belgrade for Internal Medicine/Rheumatology and has practiced medicine at the Institute of Rheumatology in Belgrade.

Bill Swavely joined Pharm-Olam International in 2017 as the Chief Information Officer (CIO). As the CIO, Mr. Swavely will be responsible for the executive oversight of Pharm-Olam’s technology portfolio and innovation.

Mr. Swavely brings more than 25 years of experience leading enterprise Information Technology in healthcare, medical devices, digital health, entertainment, private equity, and telecommunications companies. Mr. Swavely has provided technology leadership for public and private companies as well as start-up organizations.

Prior to joining Pharm-Olam, Mr. Swavely served as the Chief Innovation Officer for InfoBionic, CIO for BioTelemetry/CardioNet Inc., Chief Technology Officer (CTO) for Blue Cross of Northeastern PA, CIO at VIASYS Healthcare Inc., as well as CTO and Co-Founder at Enable Business Solutions LLC.  Mr. Swavely received his BS in Electrical and Computer Engineering from Clarkson University, and his MBA from Rensselaer Polytechnic Institute.

Daniel Burgess, BSc, FRQA, serves as Pharm-Olam’s Head of Quality and Compliance, and in this role he oversees the strategic direction and ensures the implementation of laws and regulations that affect core businesses and our relations with our customers. Mr. Burgess is also responsible for the overall direction and management of the Pharm-Olam Quality System, Global Quality Assurance and Corporate Compliance. Additionally he serves on various company oversight committees, including but not limited to Quality Forum, Operational Quality Committee, Computer System Validation Committee, Privacy Committee, Anti-Bribery Task Force, Privacy Shield/ Safe Harbor Committee etc.

Mr. Burgess brings to Pharm-Olam close to 30 years of experience in quality across the GxPs in clinical research, as well as laboratory and pharmaceutical manufacturing, within several leading pharmaceutical industry organizations, including Ipsen, Novartis, Alexion, Thermo Fisher Scientific and Pfizer. He has a BSc in Environmental Monitoring / Life Science, qualifications in Instructional Design and Research Quality Assurance, is recognized as a Fellow in Research Quality Assurance (FRQA) by his peers and is a speaker / tutor for a number of international quality associations.

 

Asif Sayani is the General Counsel for Pharm-Olam International. As General Counsel, Mr. Sayani is the chief legal officer and is responsible for advising the company on legal matters and risks as well as supervising teams who do the same.

Prior to joining Pharm-Olam, Mr. Sayani previously was a Partner at Sayani Law Firm, PPLC. Other previous roles included Adjunct Professor of Law at the University of Houston Law Center, General Counsel to OPEN Houston, Chair of the South West Council for the Ismaili Professionals Network, and Assistant Corporation Counsel for the City of Chicago.

Asif joined Pharm-Olam in 2016.